A documented deviation. A signed CAPA. A closed investigation. And a single question, asked on day two of inspection, that the file does not answer.
. The investigator pulls Complaint COMP-2024-0312. A patient reported tablet appearance variation in Losartan Potassium Tablets 50 mg, Lot 2024-0623 — small white spots on some tablets in a single bottle.
The investigation team examined the retain sample. Found similar low-incidence cosmetic variation in the retain. The conclusion: cosmetic variation only, no impact on patient safety or product performance. No further action. Complaint closed.
The investigator turns to the conclusion.
Most QA teams answer this question verbally. The file does not contain the documented reasoning. That is the gap.
Skip ahead to the record format →Complaint investigations concluding no-action without documented patient safety evaluation are commonly cited in 483 observations, particularly for products with serious indications. The pattern: visual examination performed, cosmetic conclusion drawn, no documented evaluation of broader implications.
The retain sample was examined visually. Similar low-incidence appearance variation was identified. Patient safety implications were considered. The Complaint Investigator signed the closure. The patient was sent a courtesy response.
What the file contained was the conclusion.
What the file did not contain was the decision.
A retain examination was performed. A cosmetic-only conclusion was reached. A no-action determination was authorized. But the rationale for limiting examination to the retain sample, the documented evaluation of patient safety beyond visual inspection, and the named individual who authorized the no-action determination are not in the file.
The conclusion belongs in the file. The decision belongs in the record.
Under ICH Q10 and post-market surveillance expectations, the rigor required for a no-action conclusion increases when the complaint involves a tablet appearance change that could indicate formulation, manufacturing, or packaging issues affecting other lots.
The investigation must demonstrate — in writing, contemporaneous with the determination — that patient safety was evaluated beyond visual inspection, that other lots in the manufacturing campaign were considered, and that the named authorizing individual reviewed the evidence before concluding no action.
A retain visual examination is data. A retain visual examination is not, on its own, a documented complaint disposition.
The complaint file documents the closure. It does not document who decided there was no action, on what evidence, against what alternatives, and under what authority.
That 483 was avoidable.
The five fields the investigator expects to find. The alternative-causes evaluation that distinguishes a decision from a signature. A complete reference example from the Vancomycin scenario.
Show Me the Record →Used by Quality and Validation leaders preparing for FDA and EMA inspections. Built around 21 CFR 211.192 and ICH Q9.